• Reviva Pharmaceuticals Holdings Inc RVPH.OQ reported a quarterly adjusted loss of 46 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of $-2.60. The mean expectation of five analysts for the quarter was for a loss of 62 cents per share. Wall Street expected results to range from $-1.20 to -29 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Reviva Pharmaceuticals Holdings Inc's reported EPS for the quarter was a loss of 46 cents​.

• The company reported a quarterly loss of $3.2 million.

• Reviva Pharmaceuticals Holdings Inc shares had risen by 9.0% this quarter and lost 85.7% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 48.2% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Reviva Pharmaceuticals Holdings Inc is $30.00, about 98.8% above its last closing price of $0.35

This summary was machine generated from LSEG data May 13 at 11:07 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)